1. Home
  2. APRE vs BBGI Comparison

APRE vs BBGI Comparison

Compare APRE & BBGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.74

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Logo Beasley Broadcast Group Inc.

BBGI

Beasley Broadcast Group Inc.

N/A

Current Price

$25.35

Market Cap

10.5M

ML Signal

N/A

Company Overview

Basic Information
Metric
APRE
BBGI
Founded
2006
1961
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Broadcasting
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
10.5M
IPO Year
2019
1999

Fundamental Metrics

Financial Performance
Metric
APRE
BBGI
Price
$0.74
$25.35
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$4.10
N/A
AVG Volume (30 Days)
99.7K
31.1K
Earning Date
05-13-2026
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
21.22
N/A
EPS
N/A
1.77
Revenue
N/A
$232,179,463.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$14.45
Revenue Growth
N/A
69.89
52 Week Low
$0.55
$3.14
52 Week High
$2.22
$29.30

Technical Indicators

Market Signals
Indicator
APRE
BBGI
Relative Strength Index (RSI) 44.34 58.56
Support Level $0.69 $3.93
Resistance Level $0.83 $25.26
Average True Range (ATR) 0.07 2.67
MACD 0.00 0.09
Stochastic Oscillator 47.55 61.80

Price Performance

Historical Comparison
APRE
BBGI

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

About BBGI Beasley Broadcast Group Inc.

Beasley Broadcast Group Inc is a multi-platform media company, whose primary business is operating radio stations throughout the United States. The company offers local and national advertisers integrated marketing solutions across audio, digital and event platforms. It owns and operates stations in the following markets: Atlanta, GA, Augusta, GA, Boston, MA, Charlotte, NC, Detroit, MI, Fayetteville, NC, Fort Myers-Naples, FL, Las Vegas, NV, Middlesex, NJ, Monmouth, NJ, Morristown, NJ, Philadelphia, PA, Tampa-Saint Petersburg, FL, and Wilmington, DE. The company operates in two segments Audio and Digital.

Share on Social Networks: